StockData
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. (XENE) stock

XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.78−0.48 (-1.22%)

Close on Nov 17, 2026Market cap $3.76BP/E –Yield –

Xenon Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Xenon Pharmaceuticals's price to sales ratio was 461.2× on Feb 27, 2026, against 261.8× a year earlier. Over the last 5 years it ranged from 12.5× to 461.2×, with a median of 70.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Feb 27, 2026461.2×+0.3
2025Dec 31, 2025460.9×+193.6
2023Apr 28, 2023267.2×+80.0
2022Dec 30, 2022187.2×+122.1
2021Dec 31, 202165.2×+47.4
2020Dec 31, 202017.7×−335.3
2018Apr 30, 2018353.0×+277.2
2017Dec 29, 201775.8×+46.2
2016Dec 30, 201629.6×+22.9
2015Dec 31, 20156.7×+5.8
2014Dec 31, 20140.9×–

More Xenon Pharmaceuticals figures

See a number that looks wrong?